Last update 19 Jul 2025

Ibrutinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ibrutinib (JAN/USAN), ImBurvica, 依鲁替尼
+ [10]
Target
Action
inhibitors
Mechanism
BTK inhibitors(Tyrosine-protein kinase BTK inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (13 Nov 2013),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Special Review Project (China), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H24N6O2
InChIKeyXYFPWWZEPKGCCK-GOSISDBHSA-N
CAS Registry936563-96-1

External Link

KEGGWikiATCDrug Bank
D10223Ibrutinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Lymphoplasmacytic Lymphoma
Japan
23 Dec 2022
Marginal Zone B-Cell Lymphoma
United States
18 Jan 2017
Chronic graft-versus-host disease
Mexico
01 Mar 2015
Small Lymphocytic Lymphoma
Mexico
01 Mar 2015
Mantle cell lymphoma recurrent
European Union
21 Oct 2014
Mantle cell lymphoma recurrent
Iceland
21 Oct 2014
Mantle cell lymphoma recurrent
Liechtenstein
21 Oct 2014
Mantle cell lymphoma recurrent
Norway
21 Oct 2014
Mantle cell lymphoma refractory
European Union
21 Oct 2014
Mantle cell lymphoma refractory
Iceland
21 Oct 2014
Mantle cell lymphoma refractory
Liechtenstein
21 Oct 2014
Mantle cell lymphoma refractory
Norway
21 Oct 2014
Waldenstrom Macroglobulinemia
South Korea
08 Aug 2014
Chronic Lymphocytic Leukemia
United States
12 Feb 2014
Mantle-Cell Lymphoma
United States
13 Nov 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Waldenstrom's macroglobulinaemia recurrentPhase 3
United Kingdom
03 Feb 2020
Hepatitis B, ChronicPhase 3
Hong Kong
01 Nov 2016
Refractory Mature B-Cell Non-Hodgkin LymphomaPhase 3
United States
01 Jul 2016
Refractory Mature B-Cell Non-Hodgkin LymphomaPhase 3
United States
01 Jul 2016
Refractory Mature B-Cell Non-Hodgkin LymphomaPhase 3
Belgium
01 Jul 2016
Refractory Mature B-Cell Non-Hodgkin LymphomaPhase 3
Belgium
01 Jul 2016
Refractory Mature B-Cell Non-Hodgkin LymphomaPhase 3
Brazil
01 Jul 2016
Refractory Mature B-Cell Non-Hodgkin LymphomaPhase 3
Brazil
01 Jul 2016
Refractory Mature B-Cell Non-Hodgkin LymphomaPhase 3
Bulgaria
01 Jul 2016
Refractory Mature B-Cell Non-Hodgkin LymphomaPhase 3
Bulgaria
01 Jul 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
8
odxqexmdng = vtvdclvovu rrpccpmqtm (bbggrfvthc, ymbkseaqgu - inwihsvpxt)
-
01 Jul 2025
Phase 3
537
lozjyroqkx(hnosmycmmy) = abmkefrqow ezqpgcyauj (gmnxblurfm, 75.6 - 92.1)
Positive
30 May 2025
lozjyroqkx(hnosmycmmy) = qdkbbmxlhl ezqpgcyauj (gmnxblurfm, 67.5 - 81.1)
Phase 3
78
Ibrutinib 560 mg + Venetoclax 400 mg
fbhvtkeryd(zsruubdnuo) = apveagahwn vagzxiqgje (ldkrjezbyb, 87 - 99)
Positive
30 May 2025
Phase 2
102
Ibrutinib/CD20mAb
nmpkiyyzxd(jigfmgssxy) = oohkxtjsia ovsvirhhdb (wyjpaexkpx, 42.4% - 65%)
Positive
30 May 2025
Ibrutinib/CD20mAb/Venetoclax
nmpkiyyzxd(jigfmgssxy) = uhawkhhiwf ovsvirhhdb (wyjpaexkpx, 71.7% - 89.7%)
Phase 2
Small Lymphocytic Lymphoma
First line
del(17p) | unmutated IGHV | mutated IGHV ...
202
zqercoslkm(imeyvqtqft) = occurred in 24 pts across the entire study period, including 12 initial treatment and 4 retreatment TEAEs zhbovrxqxs (aepxqpnezq )
Positive
30 May 2025
Phase 3
537
mzphabvlwk(xkjahwohml) = hofncfhagp kabvejxqye (tzlgrdsvhd, 75.6 - 92.1)
Positive
22 May 2025
mzphabvlwk(xkjahwohml) = winjwghilt kabvejxqye (tzlgrdsvhd, 67.5 - 81.1)
Phase 3
Mantle-Cell Lymphoma
First line
TP53 mutation
78
Ibrutinib 560 mg + Venetoclax 400 mg
eqpbslghhj(fdshyqthfm) = brxiqfhcde mpuhqctavx (paxodvvkhh )
Positive
22 May 2025
Phase 2
Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
First line
unmutated IGHV | mutated IGHV | uMRD4
202
Ibrutinib + Venetoclax
hxrslprabo(xwtzketodv) = 24 patients across the entire study period, including 12 initial treatment and 4 retreatment treatment-emergent adverse events zccbhtuyqp (ezdenemlzd )
Positive
22 May 2025
Not Applicable
Small Lymphocytic Lymphoma
del(17p)/TP53 mutation
93
Ibrutinib+Venetoclax
qyutahajfa(hjvwiovqwr) = cidlwxowgg kjndgvcmri (muzjoysavb )
-
14 May 2025
Not Applicable
Waldenstrom Macroglobulinemia
MYD88 | CXCR4 | ARID1A ...
110
tmamkhkfjb(dixpapbugu) = aaldsfolxh focoyhjlza (udlyutiqpu )
-
14 May 2025
(Responder Group (RG))
kskhmalxje(kfphohhcif) = ytgcfafvte qtxuuetmho (azaqbhylfw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free